Articles
A new view for an old disease
SSADA software, coupled with OCT angiography shows potential in diagnosing, monitoring glaucoma.
By David Huang, MD, PhD
A novel way to use an old technology
Clinicians, researchers look at early clinical implications of DME using fundus autofluorescence.
By Vanessa Caceres, Contributing
A system born out of need, demand
Femtosecond laser cataract surgery suites help guide surgeons to accurate results.
By Zack Tertel, managing editor
Care shouldn’t end with vision loss
Your number of low-vision patients is likely to increase in coming years; be prepared.
By Karen Auge, Contributing
How to choose the right anti-VEGF
With three to choose from, it’s important to know the seminal studies and what works for DME patients.
By Sanket U. Shah, MD, and
Quick Hits
By Robert Stoneback, associate editor
SPOTLIGHT ON TECHNOLOGY & TECHNIQUE
A wider spectrum of vision care
By Robert Stoneback, associate editor
Telehealth reaches the unreachable
Internists, ophthalmologists team up remotely to screen diabetics, and find those with sight-threatening disease.
By Karen Blum, Contributing
The current-care toolbox for DME
Know your technologies, especially OCT. As for drug therapies, you’ll need to be intimate with the Big Three.
By Michael P. Hood, MD
Trends in early diabetes diagnosis
Recent research could help clinicians get a handle on complications sooner.
By Elizabeth R. Gaillard, PhD
Viewpoint
Bigger boats and larger toolboxes
When selling, plan and be patient
Before you develop an exit strategy when selling your practice, know what to expect.
By Robert Calandra, Contributing
Branded Preferred
Clinicians discuss the settings in which they prefer branded drugs and why.
By Virginia Pickles, Contributing
Equivalent But Not Exactly the Same
Despite strict FDA oversight, the potential for small differences exists between generic ophthalmic drugs and their branded counterparts.
By Virginia Pickles, Contributing
How to Ensure a Drug is Dispensed as Written
Educating patients about the differences between brand-name and generic ophthalmic drugs is one of several effective strategies.
By Virginia Pickles, Contributing
Q&A with FDA
Ophthalmology Management asked the FDA to answer some questions about generic medications. FDA spokesperson Timothy Irvin provided these responses.